Preinception-stage biotech in immuno-oncology with an international team of experts and founders aiming to develop personalized therapeutics against multiple myeloma and Seed raising of $10M.
In Apoliktos, we are working on a novel neo concept against cancer. We aspire to help develop a personalized therapy for patients in 3 to 7 days.
First, with the help of the physician, we would evolve the diagnostic and perform a patient stratification.
Then, we would be able to develop a personalized patient approach using tumor-mutation binders combined with the immunotherapy that would improve dramatically the approach. This combination would happen right at the bedside.
Finally, the patient would receive a heavily personalized immuno-therapy treatment.